Imaging, Retina/Vitreous
Read Time: 2 mins

Diabetic Macular Oedema and Retinal Imaging

Copy Link
Published Online: Aug 11th 2017 European Ophthalmic Review, 2017;11(1):21–2 DOI:
Authors: Maurizio Battaglia Parodi
Quick Links:
Article Information

Many important eye diseases manifest themselves in the retina, one of the most prevalent of these is diabetic macular oedema. Retinal imaging and image analysis have developed rapidly over the past 10 years, and image analysis is starting to play an important role in the care of patients with retinal diseases. In advance of this year’s EURETINA congress, European Ophthalmic Review’s Editor-in-Chief, Maurizio Battaglia Parodi, of the University Vita-Salute, Milan, Italy, discusses the continuing role of laser treatment in clinically significant macular oedema, retinal imaging and image analysis methods.

Q: In the era of intravitreal pharmacological treatments, what is the role of laser treatment for clinically significant macular oedema?
Laser is not dead. Although intravitreal drugs including anti-vascular endothelial growth factor (VEGF) and steroids, represent the typical approach for macular oedema in general, laser treatment can still be useful. In particular, laser application can provide results similar to anti- VEGF molecules in thinner diabetic macular oedema. In addition, Diabetic Retinopathy Clinical Research Network (DRCRnet) data at 5 years support the efficacy of a combined therapy laser and ranibizumab in the management of diabetic macular edema. Moreover, some cases of macular oedema associated with diabetic retinopathy and retinal vein occlusion, can benefit from peripheral laser photocoagulation in an attempt to reduce both up-regulation and release of VEGF. Lastly, I would like to underline that laser treatment in general is now shifting to new laser applications, scheduling subthreshold treatment in order to minimise the retinal damage preserving the effects.

Q: Which presentations are you most looking forward to watching at this year’s EURETINA congress?
I am particularly interested in the new treatments of retinal dystrophies, including gene therapy and stem cell therapy bearing in mind the terrible socioeconomical burden they carry on people affected.

Q: What has been the impact of the availability of optical coherence tomography angiography on retinal imaging?
With the advent of optical coherence tomography angiography (OCTA), we can investigate the retinal vascular architecture in a more feasible way with respect to fluorescein angiography/ guided indocyanine green angiography (FA/ICGA), allowing also a better visualisation of deeper retinal vessels and the choriocapillaris. Moreover, OCTA information can be implemented by the use of currently evolving post-processing techniques; thus, providing us with more precise both qualitative and quantitative data, which can potentially have a direct impact on clinical and research purposes. We expect that in the near future OCTA can replace FA/ICGA imaging in a number of retinal diseases.

Q: What are the major challenges in the interpretation and analysis of optical coherence tomography angiography?
First of all, due to the even more sophisticated developments, the most important challenge for any common ophthalmologist is that OCTA imaging interpretation requires familiarity with post-processing techniques. Secondly, although OCTA provides a large amount of ‘static’ information, it is less able to provide dynamic information regarding the precise blood flow in the three most important slabs. Finally, since it is currently only possible to study the motion signal in a given range of speed values, the information provided by OCTA is limited, and does not encompass all features of the retinal vascular network.

Q: What are the latest developments in imaging of individual cells in the retina?
I am more and more fascinated by the visualisation of photoreceptors and retinal pigment epithelium cells, by means of adaptive optics techniques. I believe that, in the near future, a large clinical application of these techniques can help differentiate diseases and address the therapeutic choices in a number of retinal disorders, including age-related macular degeneration, dystrophies and vascular diseases.

Article Information:

Maurizio Battaglia Parodi has nothing to declare in relation to this article. No funding was received for the publication of this article. This is an expert interview and as such has not undergone the journal’s standard peer review process.
Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.


Maurizio Battaglia Parodi, Department of Ophthalmology, Vita-Salute University, Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, Italy. E:


This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.



Further Resources

Share this Article
Related Content In Retina/Vitreous
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72